VANI

Vivani Medical Inc. (VANI) | Rumor.io

Vivani Medical

VANI

Attention (50-day avg)0%

Attention rank (50-day avg)#2,705

Bullish sentiment (50-day avg)93%

Price to earnings ratio-2.92

Market capitalization112.8M

Earnings per share-0.36

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-26.6M

Social

What share of all stock conversation is about VANI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Jul 7

Vivani Medical, Inc. (VANI) has entered into an agreement with Novo Nordisk to evaluate NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management.
The agreement allows Novo Nordisk to conduct a non-exclusive internal evaluation of semaglutide implants prepared by Vivani, utilizing the company's NanoPortal platform technology.
Vivani Medical's stock price has seen significant movement following the announcement, with some analysts predicting a potential price target of $2.85, pending further developments or deals.

Generated by AI

Sentiment

Of the messages about VANI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +7.41	91.56% +1.2
Bearish	—	—	0% -7.41	8.44% -1.2

Bullish· Jul 7

Vivani Medical, Inc. ($VANI) has seen significant growth, with its market cap increasing from $40.4 million to $165 million.
The company's cash burn has decreased by over 50% following a recent deal, reducing the need to sell shares in the near term.
With a strong market presence and potential for further growth, analysts are adjusting their price target for $VANI to around $2.85.

Bearish· Jun 13

$VANI's volume has been artificially suppressed, with an average of 144K shares traded per day since April 1, despite a 2.7MM share print on April 1.
Short sellers have not had to cover their positions, suggesting a lack of buying interest and a potentially overextended market.
The stock's recent price drop and lack of reaction to positive news suggests it may be a "trash dump" with limited fundamental value.

Generated by AI

Topics

Of the messages about VANI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	93.68%
Controversies	0%	0%	0%	0.26%
Analysts	0%	0%	0%	4.47%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0.26%
Technical Analysis	0%	0%	0%	1.32%

Announcements· Aug 8

Vivani Medical's long-acting GLP-1 implant could address adherence issues and reduce side effects in obesity treatment.
The company is poised to capitalize on the growing obesity market, projected to exceed $100 billion annually.
Upcoming human trials are expected to validate strong preclinical results for Vivani's obesity treatment technology.

Technical Analysis· Feb 28

$VANI is now down into its demand zone, where the author wants it to be.
The EMA crossover indicator on $VANI has triggered a buy signal at $4.22.
$VANI has broken through resistance and is showing signs of a potential breakout, with the author expecting it to continue moving up.

Generated by AI

Community

Of the messages about VANI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	3.96%	31.89%
Newcomers	100%	100%	96.04%	68.11%

Jul 25

Newcomers are excited about Vivani Medical's potential to revolutionize the medical field with its weight loss drug, seeing it as a game-changer in addressing the global obesity crisis.
The focus is on Vivani Medical's innovative approach to treating obesity, a major risk factor for numerous health problems, and its potential to make a significant impact on the medical and scientific communities.
Vivani Medical's weight loss drug is seen as a promising solution to a pressing global health issue, with many newcomers expressing enthusiasm and curiosity about the company's breakthrough technology.

Generated by AI

News

Vivani Medical announces anticipated October closing of Cortigent merger with ClearOne

13d agoInvesting.com

Vivani Medical at H.C. Wainwright conference: implant pitch gains pace

18d agoInvesting.com

Vivani Medical Announces Participation in Upcoming Investor Conferences

ALAMEDA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants utilizing its proprietary NanoPortal™ technology, today announced its planned participation in two upcoming investor conferences: Lake Street Capital Markets 10th Annual Best Ideas Growth ConferenceSeptember 10, 2026Metropolitan ClubNew York, New YorkH.C. Wainwright 28th Annual Global

26d agoYahoo! Finance Canada

Lake Street Remains a Buy on Vivani Medical (VANI)

Detailed price information for Vivani Medical Inc (VANI-Q) from The Globe and Mail including charting and trades.

1mo agotheglobeandmail.com

Vivani Medical: Q2 Earnings Snapshot

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

1mo agoYahoo Finance

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data expected in November 2026 Company entered into non-exclusive agreement with Novo Nordisk to evaluate NPM-139 and Vivani's proprietary NanoPortal™ technology Completion of the Cortigent-ClearOne merger into Cortigent Holdings and initiation of trading on the Nasdaq exchange under ticker symbol CRGT an

1mo agoYahoo Finance

Also Discussed

Investors talking about VANI also mention

#	Name	Attention
1	Entera Bio Ltd.ENTX	0%new
2	SLGG - Super League Enterprise, Inc.	——
3	TKAT - Takung Art Co., Ltd.	——
4	National Vision Holdings, Inc.EYE	0%0
5	VERY - Vericity, Inc.	——
6	Jiayin Group Inc. ADRJFIN	0%new
7	MediciNova Inc.MNOV	0.01%-0.01
8	OPGN - OpGen, Inc.	——
9	EpicQuest Education Group International LimitedEEIQ	0%0
10	Innsuites Hospitality TrustIHT	0%new

Vivani Medical Inc.

Healthcare
Biotechnology

Vivani Medical Inc. is a specialized biotechnology and medical device company focused on developing innovative solutions in the healthcare sector. Their primary focus is on addressing chronic diseases and improving patient outcomes through the integration of advanced technologies in bioelectronics. Vivani Medical is particularly notable for its work in creating cutting-edge, implantable medical devices designed to enhance the quality of life for individuals living with sensory deficits and chronic pain. This company operates at the intersection of bioengineering and healthcare, pioneering efforts in providing long-term therapeutic solutions. With a commitment to improving health outcomes, Vivani Medical's developments have potential implications across various medical fields, including neuroscience and chronic disease management, thus playing a significant role in the evolving landscape of medical technology. Their innovative approach underscores the growing importance of bioelectronic medicine as an emerging field that holds promise for addressing some of the most challenging health issues.

Website

Location

1350 South Loop Road

Alameda, CA, 94502

United States

Social

What share of all stock conversation is about VANI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Jul 7

Vivani Medical, Inc. (VANI) has entered into an agreement with Novo Nordisk to evaluate NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management.
The agreement allows Novo Nordisk to conduct a non-exclusive internal evaluation of semaglutide implants prepared by Vivani, utilizing the company's NanoPortal platform technology.
Vivani Medical's stock price has seen significant movement following the announcement, with some analysts predicting a potential price target of $2.85, pending further developments or deals.

Generated by AI

Sentiment

Of the messages about VANI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +7.41	91.56% +1.2
Bearish	—	—	0% -7.41	8.44% -1.2

Bullish· Jul 7

Vivani Medical, Inc. ($VANI) has seen significant growth, with its market cap increasing from $40.4 million to $165 million.
The company's cash burn has decreased by over 50% following a recent deal, reducing the need to sell shares in the near term.
With a strong market presence and potential for further growth, analysts are adjusting their price target for $VANI to around $2.85.

Bearish· Jun 13

$VANI's volume has been artificially suppressed, with an average of 144K shares traded per day since April 1, despite a 2.7MM share print on April 1.
Short sellers have not had to cover their positions, suggesting a lack of buying interest and a potentially overextended market.
The stock's recent price drop and lack of reaction to positive news suggests it may be a "trash dump" with limited fundamental value.

Generated by AI

Topics

Of the messages about VANI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	93.68%
Controversies	0%	0%	0%	0.26%
Analysts	0%	0%	0%	4.47%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0.26%
Technical Analysis	0%	0%	0%	1.32%

Announcements· Aug 8

Vivani Medical's long-acting GLP-1 implant could address adherence issues and reduce side effects in obesity treatment.
The company is poised to capitalize on the growing obesity market, projected to exceed $100 billion annually.
Upcoming human trials are expected to validate strong preclinical results for Vivani's obesity treatment technology.

Technical Analysis· Feb 28

$VANI is now down into its demand zone, where the author wants it to be.
The EMA crossover indicator on $VANI has triggered a buy signal at $4.22.
$VANI has broken through resistance and is showing signs of a potential breakout, with the author expecting it to continue moving up.

Generated by AI

Community

Of the messages about VANI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	3.96%	31.89%
Newcomers	100%	100%	96.04%	68.11%

Jul 25

Newcomers are excited about Vivani Medical's potential to revolutionize the medical field with its weight loss drug, seeing it as a game-changer in addressing the global obesity crisis.
The focus is on Vivani Medical's innovative approach to treating obesity, a major risk factor for numerous health problems, and its potential to make a significant impact on the medical and scientific communities.
Vivani Medical's weight loss drug is seen as a promising solution to a pressing global health issue, with many newcomers expressing enthusiasm and curiosity about the company's breakthrough technology.

Generated by AI

Vivani Medical

Social

Jul 7

Bullish· Jul 7

Bearish· Jun 13

Announcements· Aug 8

Technical Analysis· Feb 28

Jul 25

Vivani Medical announces anticipated October closing of Cortigent merger with ClearOne

Vivani Medical at H.C. Wainwright conference: implant pitch gains pace

Vivani Medical Announces Participation in Upcoming Investor Conferences

Lake Street Remains a Buy on Vivani Medical (VANI)

Vivani Medical: Q2 Earnings Snapshot

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

Also Discussed

Vivani Medical Inc.

Company Information

Location

Vivani Medical announces anticipated October closing of Cortigent merger with ClearOne

Vivani Medical at H.C. Wainwright conference: implant pitch gains pace

Vivani Medical Announces Participation in Upcoming Investor Conferences

Lake Street Remains a Buy on Vivani Medical (VANI)

Vivani Medical: Q2 Earnings Snapshot

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

Also Discussed

Social

Jul 7

Bullish· Jul 7

Bearish· Jun 13

Announcements· Aug 8

Technical Analysis· Feb 28

Jul 25